Dr. Al-Kali is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
200 1st Street SW
Rochester, MN 55905- Is this information wrong?
Education & Training
- University of Texas M.D. Anderson Cancer CenterFellowship, Leukemia, 2009 - 2010
- University of Oklahoma Health Sciences CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
- Western Reserve Health Education/NEOMEDResidency, Internal Medicine, 2003 - 2006
- Damascus University Faculty of MedicineClass of 2000
Certifications & Licensure
- CT State Medical License 2017 - 2024
- OK State Medical License 2006 - 2024
- MN State Medical License 2010 - 2024
- TX State Medical License 2009 - 2012
- OH State Medical License 2002 - 2007
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Kimberly Patterson Leukemia Research award UT MD Anderson Cancer Center, 2010
- Merit Award American Society of Hematology, 2009
- Internal Medicine Resident Top Educators Mayo Clinic, 2012
- Join now to see all
Clinical Trials
- Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome Start of enrollment: 2012 May 01
- Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2015 Mar 12
- Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs Start of enrollment: 2013 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance.Marissa M Li, Anmol Baranwal, Mark Gurney, Syed Naseem Shah, Aref Al-Kali, Hassan B Alkhateeb, James M Foran, Cecilia Arana-Yi, Laura Ongie, Dong Chen, Abhishek A Mang...> ;Blood Advances. 2024 Apr 2
- Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.Nickolas Steinauer, Kristen McCullough, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Torghabeh, Mark R Litzow, Wi...> ;Haematologica. 2024 Mar 28
- Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant.Ayalew Tefferi, Animesh Pardanani, Kebede H Begna, Aref Al-Kali, William J Hogan, Mark R Litzow, Rhett P Ketterling, Kaaren K Reichard, Naseema Gangat> ;Blood Cancer Journal. 2024 Mar 19
- Join now to see all
Journal Articles
- Monosomal Karyotype Predicts Adverse Prognosis in Patients Diagnosed with Chronic Myelomonocytic Leukemia (CMML): A Single Institution ExperienceA Alsahlawi, H Alkhateeb, M Patnaik, K Begna, M Elliott, W Hogan, M Litzow, A Al-Kali, Clinical Lymphoma, Myeloma and Leukemia, 6/10/2014
- Toxoplasmosis in Patients with hematologic MalignanciesA Chintakuntlawar, M Kidd, A Al-Kali, W Wilson, CA Thompson, Leuk Lymphoma, 5/31/2014
- Genetic Determinants of Response and Survival in Momelotinib Treated Patients with MyelofibrosisPardanani A, Abdelrahman RA, Finke C, Lasho T, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Hanson CA, Ketterling RP, Tefferi A, Leukemia, 1/1/2014
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- DNA Cytosine-Demethylating Agent 5-Aza-2'-Deoxycytidine Targets Leukemia Cells through Reducing DNA N6-MethyladenineAref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...Aref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be BeneficialAref Al-Kali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- A phase II study (NCI9775) of sapanisertib (MLN0128/TAK-228) in relapsed and/or refractory acute lymphoblastic leukemia (ALL): Interim analysis.2019 ASCO Annual Meeting - 6/1/2019
- A Phase II of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Hematological Emergencies in the ICU8/19/2014
- Join now to see all
Authored Content
- ASH 2018: The Current State of Myeloid MalignanciesDecember 2018
- ASH 2018: The Current State of Myeloid MalignanciesDecember 2018
Press Mentions
- Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual MeetingMay 22nd, 2017
- Ongoing AML Trials of Novel Agents Could Shift FieldMay 15th, 2017
Committees
- member, NCCN MDS committee 2016 - Present
Professional Memberships
- Member
- Member
- Member
Other Languages
- Arabic
Hospital Affiliations
- Mayo Clinic Hospital - RochesterRochester, Minnesota
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: